Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro laboratory research
PubMed 10398297 · doi:10.1002/(SICI)1097-4547(19990715)57:2<195::AID-JNR5>3.0.CO;2-P
What was done
Adult mice and rats were subjected to dietary restriction (DR) prior to exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In parallel, ad libitum-fed mice received the nonmetabolizable glucose analogue 2-deoxy-D-glucose (2-DG) before MPTP treatment. In vitro, cultured dopaminergic cells were pretreated with 2-DG and exposed to the mitochondrial complex I inhibitor rotenone or to Fe2+. The researchers measured substantia nigra dopaminergic neuron survival, motor performance, oxidative stress, mitochondrial function, and expression of the cytoprotective stress proteins HSP-70 and GRP-78.
What was found
The abstract reports no numerical values, sample sizes, or effect sizes. Qualitatively, DR protected mice and rats against MPTP-induced dopaminergic neuron loss in the substantia nigra and ameliorated motor deficits. Treatment with 2-DG similarly reduced dopaminergic neuron loss and improved behavioral outcomes in MPTP-treated mice. In cell culture, 2-DG suppressed oxidative stress, preserved mitochondrial function, and attenuated cell death induced by rotenone or Fe2+. Both DR and 2-DG induced expression of heat-shock protein 70 and glucose-regulated protein 78 in dopaminergic cells.
Why it matters
This work demonstrates that metabolic preconditioning via dietary restriction or glycolytic inhibition can induce cytoprotective stress responses that protect dopaminergic neurons in experimental toxin models of Parkinson's disease.
Limits
The study is entirely preclinical, relying on acute rodent neurotoxin models (MPTP) and in vitro systems (rotenone, Fe2+), which do not fully replicate the chronic, progressive etiology of human Parkinson's disease. The abstract provides no sample sizes, dosages, quantitative measurements, or statistical significance metrics. Clinical safety and efficacy of 2-DG or dietary restriction in humans were not evaluated.
Cited by
- supports Administering 2-deoxyglucose every other day is neuroprotective in animal models.